Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Taylor Mader (NPI 1871888487)

Field	Value
Entity Type	Individual
Organization	Taylor Mader
Address	210 Overland Dr
City	Greenwood
State	SC
ZIP	29646
Taxonomy	Rheumatology Physician
NPI Enumerated	June 10, 2011

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider’s Medicare activity dominates their billed care: total Medicare revenue is $3.1M while Medicaid is listed as none, so the practice is effectively single‑payer (Medicare) in the available claims data. That concentration suggests payer contracting and reimbursement trends for Medicare will disproportionately influence overall revenue and utilization metrics.

Revenue is highly concentrated in a small set of biologic administration codes: the precomputed top‑3 Medicare codes account for 76.3% of this provider’s Medicare revenue, driven by J0129 ($1.2M, 37.7%), J3262 ($709.9K, 22.7%), and J0717 ($498.4K, 15.9%). This heavy reliance on three injectable biologic codes indicates most clinical revenue is tied to high‑cost specialty drugs administered in the office.

The mix of top CPT/HCPCS codes indicates an infusion‑and‑injection oriented rheumatology practice: J0129 and J0717 explicitly note use when drugs are administered under direct physician supervision, and other high‑revenue biologics listed (J3262, J1602, J1745) are also injectable or intravenous agents. These code descriptions imply in‑office infusion capacity and nursing support rather than a pure ambulatory E&M‑only model.

On competitive standing for specific biologics, the provider is a high‑volume national outlier for some drugs: J0129 ranks #29 of 1221 providers nationally (98th percentile; notably above typical national volume for this code) and J3262 ranks #21 of 618 providers nationally (97th percentile; notably above typical national volume for this code). Those ranks place the provider well above typical national peers for abatacept and tocilizumab administration.

Other biologic and infusion codes show more typical national participation: J0717 ranks #98 of 848 (89th percentile; typical, unremarkable volume), J1602 ranks #157 of 1041 (85th percentile; typical, unremarkable volume), and J1745 ranks #367 of 1352 (73th percentile; typical, unremarkable volume). These placements suggest exceptional concentration in a couple of agents but otherwise a broadly typical profile for other infusion products.

Visit and procedure coding supports a procedural, infusion‑heavy throughput in addition to drug administration: 99214 produced $82.5K (927 claims, 2.6% of Medicare revenue) and ranks #13820 of 479517 providers nationally (97th percentile; notably above typical national volume), while infusion/administration codes 96365 (621 claims, $29.8K; 97th percentile) and 96372 (750 claims, $8.3K; 99th percentile) are also notably above typical national volume. Taken together, high E&M and infusion administration ranks indicate the practice pairs biologic delivery with substantial office‑based patient management and procedural throughput.

Laboratory testing patterns are consistent with rheumatology monitoring rather than primary‑care screening: examples include CRP testing 86140 (578 claims, $2.9K), cyclic citrullinated peptide 86200 (35 claims, $420), and rheumatoid factor 86431 (24 claims, $120). These modest laboratory revenues align with specialist monitoring protocols that support biologic treatment decisions and disease activity assessment.

The provider has an established enrollment history (NPI enumerated 2011-06-10 (~15 years ago)), which corresponds with the sustained, high‑volume biologic administration observed. Longevity in the Medicare file may help explain the development of infusion capacity and the high national ranks for select injectable agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

24 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	34,650	$30	$1.2M
J3262	Injection, tocilizumab, 1 mg	141,980	$10	$709.9K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	124,600	$1	$498.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	30,010	$10	$300.1K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,120	$30	$133.1K
J0897	Injection, denosumab, 1 mg	5,640	$20	$101.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	930	$90	$82.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	390	$100	$37.8K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	620	$50	$29.8K
86480	The lab analyst performs a test to evaluate a cell mediated immunity gamma interferon antigen response to certain tuberculosis, or TB, antibodies.	150	$60	$9.1K

Showing 1–10 of 24

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Taylor Mader — 5 of 24 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

24 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	3	40	9,640	$30	$424.2K
J0717	5	20	59,200	$1	$278.4K
J1602	15	40	23,560	$10	$264.5K
J3262	1	20	40,900	$1	$202.7K
J1745	15	50	3,250	$30	$107K
J0897	57	250	2,400	$20	$91.2K
99214	498	7,860	160	$80	$23.2K
96413	36	150	140	$90	$22.1K
99213	3,786	7,690	100	$60	$10.8K
96365	5	170	100	$40	$7.4K

Showing 1–10 of 24

Related Providers

Other providers that share a Tax Identification Number (TIN) with Taylor Mader, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
William Chafin	GA	Rheumatology Physician	$3.3M	$0
Dean Stephens	GA	Rheumatology Physician	$2.7M	$0
Charles Degenhardt	GA	Rheumatology Physician	$2.4M	$0
Paul Sutej	GA	Rheumatology Physician	$2.4M	$0
Durga Adhikari	SC	Rheumatology Physician	$2.4M	$0
Marta Bognar	GA	Rheumatology Physician	$2.3M	$0
Brent Flickinger	GA	Rheumatology Physician	$2.3M	$0
Kathleen Flint	SC	Rheumatology Physician	$2.3M	$0
Colin Edgerton	SC	Rheumatology Physician	$1.9M	$0
John Brittis	SC	Rheumatology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Taylor Mader, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Self Regional Healthcare	SC	General Acute Care Hospital	$0	$58.8M
Greenwood Genetic Center Lab	SC	Clinical Medical Laboratory	$0	$31.2M
South Carolina Dept Of Mental Health Accounting Office	SC	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$29.1M
Carolina Health Centers, Inc.	SC	Pediatrics Physician	$0	$20.2M
Self Medical Group	SC	Emergency Medicine Physician	$0	$6M
Carolina Health Centers, Inc.	SC	Federally Qualified Health Center (FQHC)	$0	$3.3M
Greenwood Treatment Specialists	SC	Methadone Clinic	$75.9K	$3.2M
Self Medical Group	SC	Pediatrics Physician	$0	$3.3M
Greenwood County Ems	SC	Ambulance	$905.9K	$2.2M
Greenwood Obstetrics & Gynecology PA	SC	Obstetrics & Gynecology Physician	$0	$2.7M

Taylor Mader — Billing Profile & Reimbursement Data

Sign up for Taylor Mader — Billing Profile & Reimbursement Data policy alerts

Taylor Mader — Billing Profile & Reimbursement Data

Sign up for Taylor Mader — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References